BI 1815368 / Boehringer Ingelheim - LARVOL DELTA

Boehringer Ingelheim initiates Phase II study of BI 1815368, a potential first-in-class oral treatment for diabetic macular edema (GlobeNewswire) - "Boehringer Ingelheim today announces the start of the THULITE Phase II clinical study (NCT06962839). It will investigate the efficacy, safety and tolerability of BI 1815368 as a potential oral treatment to improve vision in people with diabetic macular edema (DME)."

Trial status • Diabetic Macular Edema

A Study to Test Whether BI 1815368 Helps People With an Eye Condition Called Diabetic Macular Edema (clinicaltrials.gov) - P2 | N=300 | Recruiting | Sponsor: Boehringer Ingelheim | Not yet recruiting ➔ Recruiting

Enrollment open • Diabetic Macular Edema • Macular Edema • Ophthalmology

A Study to Test Whether BI 1815368 Helps People With an Eye Condition Called Diabetic Macular Edema (clinicaltrials.gov) - P2 | N=300 | Not yet recruiting | Sponsor: Boehringer Ingelheim

New P2 trial • Diabetic Macular Edema • Macular Edema • Ophthalmology